ProShare Advisors LLC Has $442,000 Stake in PTC Therapeutics, Inc. (PTCT)
ProShare Advisors LLC lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 8.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,115 shares of the biopharmaceutical company’s stock after purchasing an additional 1,970 shares during the period. ProShare Advisors LLC owned 0.07% of PTC Therapeutics worth $442,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Alps Advisors Inc. increased its stake in shares of PTC Therapeutics by 5.6% in the 2nd quarter. Alps Advisors Inc. now owns 31,191 shares of the biopharmaceutical company’s stock worth $572,000 after purchasing an additional 1,667 shares in the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of PTC Therapeutics by 75.1% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 42,593 shares of the biopharmaceutical company’s stock worth $781,000 after purchasing an additional 18,273 shares in the last quarter. American International Group Inc. boosted its holdings in PTC Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 20,480 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 1,355 shares during the period. AXA bought a new position in PTC Therapeutics in the 1st quarter worth $103,000. Finally, Camber Capital Management LLC bought a new position in PTC Therapeutics in the 1st quarter worth $12,300,000. Hedge funds and other institutional investors own 81.30% of the company’s stock.
WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/07/proshare-advisors-llc-has-442000-stake-in-ptc-therapeutics-inc-ptct.html.
PTC Therapeutics, Inc. (NASDAQ:PTCT) opened at 19.63 on Friday. PTC Therapeutics, Inc. has a 12-month low of $4.03 and a 12-month high of $22.00. The company’s market cap is $810.80 million. The firm’s 50 day moving average is $19.60 and its 200 day moving average is $16.12.
PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.45. The business had revenue of $47.96 million during the quarter, compared to analysts’ expectations of $28.78 million. PTC Therapeutics had a negative net margin of 88.43% and a negative return on equity of 81.84%. The company’s quarterly revenue was up 206.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.14) earnings per share. Equities research analysts anticipate that PTC Therapeutics, Inc. will post ($2.34) EPS for the current fiscal year.
Several brokerages recently weighed in on PTCT. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of PTC Therapeutics in a report on Friday, September 29th. Barclays PLC dropped their target price on shares of PTC Therapeutics from $22.00 to $15.00 and set an “equal weight” rating for the company in a report on Friday, September 29th. Citigroup Inc. reaffirmed a “buy” rating and issued a $28.00 target price on shares of PTC Therapeutics in a report on Wednesday, September 27th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $25.00 target price on shares of PTC Therapeutics in a report on Tuesday, September 26th. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of PTC Therapeutics in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $17.78.
About PTC Therapeutics
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Stock Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related stocks with our FREE daily email newsletter.